Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.43 |
| ▸ | LOX | P28300 | 7/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276870 | 0.92 | MAOB (0.50) | LOXL2MAOBFNTAFNTBPGGT1B | |
| SCHEMBL3278218 | 0.86 | LOXL2 (0.43) | LOXL2LOXMAOB | |
| SCHEMBL3276867 | 0.83 | IRAK4 (0.39) | P2RX3 | |
| SCHEMBL3277572 | 0.80 | F10 (0.40) | LOXL2LOXPLAU | |
| SCHEMBL3278992 | 0.78 | HDAC1 (0.44) | LOXL2LOX | |
| SCHEMBL3278982 | 0.77 | CTSS (0.40) | — | |
| SCHEMBL3279407 | 0.73 | F2 (0.54) | — | |
| SCHEMBL8720576 | 0.73 | MAPT (0.48) | — | |
| SCHEMBL5622413 | 0.71 | KMO (0.42) | P2RX3 | |
| SCHEMBL3281929 | 0.70 | F2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | claimed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | claimed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3515559-B1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA FARBER CANCER INST INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240153580-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | Scipher Medicine Corporation | 2024-05-09 | — | — | US | disclosed |
| US-11136409-B2 | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20190202929-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018057618-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | disclosed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | USP2, UCHL3, UCHL5 | LOXL2 281/4885LOX 534/4885MAOB 924/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | LOXL2 729/4885LOX 2279/4885MAOB 4462/4885 |
| US-20190202929-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | USP10, MCL1, USP30 | LOXL2 3650/4885LOX 3873/4885MAOB 4577/4885 |
| US-11136409-B2 | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators | USP10, MCL1, USP30 | LOXL2 3650/4885LOX 3873/4885MAOB 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.